HDL: Still a target for new therapies?

S. J. Nicholls

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Residual cardiovascular risk despite lowering LDL-cholesterol has stimulated research to develop strategies that promote the protective properties of HDL-cholesterol. Population and animal studies have suggested that HDL plays an important role in protection against cardiovascular disease. As a result, considerable interest has focused on the development of new therapies that substantially raise levels of HDL-cholesterol. The highly publicized failure of the cholesteryl ester transfer protein inhibitor torcetrapib has fuelled speculation that raising HDL-cholesterol may not be a viable strategy for the development of new therapies. It has also highlighted the complexity of the relationship between HDL and protection from cardiovascular disease. Accordingly, functionality has become an important factor for consideration in the development of new agents that raise HDL-cholesterol. The evidence for the biological activity of HDL, and both existing and emerging therapeutic strategies are reviewed.

LanguageEnglish
Pages950-956
Number of pages7
JournalCurrent Opinion in Investigational Drugs
Volume9
Issue number9
Publication statusPublished - Sep 2008
Externally publishedYes

Keywords

  • Atherosclerosis
  • Cardiovascular disease
  • HDL
  • Risk factor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Nicholls, S. J. / HDL : Still a target for new therapies?. In: Current Opinion in Investigational Drugs. 2008 ; Vol. 9, No. 9. pp. 950-956.
@article{d171127c05ad46a2a315cd2376e2c920,
title = "HDL: Still a target for new therapies?",
abstract = "Residual cardiovascular risk despite lowering LDL-cholesterol has stimulated research to develop strategies that promote the protective properties of HDL-cholesterol. Population and animal studies have suggested that HDL plays an important role in protection against cardiovascular disease. As a result, considerable interest has focused on the development of new therapies that substantially raise levels of HDL-cholesterol. The highly publicized failure of the cholesteryl ester transfer protein inhibitor torcetrapib has fuelled speculation that raising HDL-cholesterol may not be a viable strategy for the development of new therapies. It has also highlighted the complexity of the relationship between HDL and protection from cardiovascular disease. Accordingly, functionality has become an important factor for consideration in the development of new agents that raise HDL-cholesterol. The evidence for the biological activity of HDL, and both existing and emerging therapeutic strategies are reviewed.",
keywords = "Atherosclerosis, Cardiovascular disease, HDL, Risk factor",
author = "Nicholls, {S. J.}",
year = "2008",
month = "9",
language = "English",
volume = "9",
pages = "950--956",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "9",

}

Nicholls, SJ 2008, 'HDL: Still a target for new therapies?', Current Opinion in Investigational Drugs, vol. 9, no. 9, pp. 950-956.

HDL : Still a target for new therapies? / Nicholls, S. J.

In: Current Opinion in Investigational Drugs, Vol. 9, No. 9, 09.2008, p. 950-956.

Research output: Contribution to journalReview article

TY - JOUR

T1 - HDL

T2 - Current Opinion in Investigational Drugs

AU - Nicholls, S. J.

PY - 2008/9

Y1 - 2008/9

N2 - Residual cardiovascular risk despite lowering LDL-cholesterol has stimulated research to develop strategies that promote the protective properties of HDL-cholesterol. Population and animal studies have suggested that HDL plays an important role in protection against cardiovascular disease. As a result, considerable interest has focused on the development of new therapies that substantially raise levels of HDL-cholesterol. The highly publicized failure of the cholesteryl ester transfer protein inhibitor torcetrapib has fuelled speculation that raising HDL-cholesterol may not be a viable strategy for the development of new therapies. It has also highlighted the complexity of the relationship between HDL and protection from cardiovascular disease. Accordingly, functionality has become an important factor for consideration in the development of new agents that raise HDL-cholesterol. The evidence for the biological activity of HDL, and both existing and emerging therapeutic strategies are reviewed.

AB - Residual cardiovascular risk despite lowering LDL-cholesterol has stimulated research to develop strategies that promote the protective properties of HDL-cholesterol. Population and animal studies have suggested that HDL plays an important role in protection against cardiovascular disease. As a result, considerable interest has focused on the development of new therapies that substantially raise levels of HDL-cholesterol. The highly publicized failure of the cholesteryl ester transfer protein inhibitor torcetrapib has fuelled speculation that raising HDL-cholesterol may not be a viable strategy for the development of new therapies. It has also highlighted the complexity of the relationship between HDL and protection from cardiovascular disease. Accordingly, functionality has become an important factor for consideration in the development of new agents that raise HDL-cholesterol. The evidence for the biological activity of HDL, and both existing and emerging therapeutic strategies are reviewed.

KW - Atherosclerosis

KW - Cardiovascular disease

KW - HDL

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=50249169416&partnerID=8YFLogxK

M3 - Review article

VL - 9

SP - 950

EP - 956

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 9

ER -